List view / Grid view
11 July 2019 | By Victoria Rees (European Pharmaceutical Review)
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
13 May 2019 | By Mike Wilson - Director Product Marketing Mass Spectrometry Systems
Biopharma developers and manufacturers need to know their molecules and understand their manufacturing processes better than ever before. In this article, Mike Wilson discusses the benefits of mass analysis in biopharma and the current challenges of adopting new technologies.
2 May 2019 | By European Pharmaceutical Review
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
28 January 2019 | By European Pharmaceutical Review
A study has reported that almost 40 percent of patients with non-surgically treatable tumours were effectively treated using a genetically modified virus...
25 May 2018 | By European Pharmaceutical Review
First proof-of-concept study shows AMG 714 (anti-IL-15 monoclonal antibody) potentially protects celiac patients from inadvertent gluten exposure
24 May 2018 | By European Pharmaceutical Review
The FDA has approved the use of Prolia for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture...
23 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...
19 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The European Commission has granted marketing authorisation for Mvasi for the treatment of certain types of cancer...
8 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture...
20 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
27 April 2017 | By Niamh Marriott, Junior Editor
Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine...
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...